Based on previous comments, there are acquisitions in the works. I would like the hospital and lab deals to close. Hopefully without the restructuring drama we have had with Veneto.

One would think the NGIO "spinoff" acquisition would be a top priority. As the study gets going there will be news flow which could help the stock value. Not to say the value, when it does come together couldn't reflect past news but it would feel that way if the stock isn't trading.

I would thing GNBT is being extra cautious at this point doing their DD.